The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2−, PIK3CA mutant or wild-type, breast cancer (BC).
Ingrid A. Mayer
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Peter A. Fasching
Consultant or Advisory Role - Genomic Health; Novartis; Roche
Honoraria - Genomic Health; Novartis; Roche
Research Funding - Amgen; Novartis
Michael Gnant
Consultant or Advisory Role - Novartis
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Lars Blumenstein
Employment or Leadership Position - Novartis
Anuradha Dutta
Employment or Leadership Position - Novartis
Caroline Germa
Employment or Leadership Position - Novartis
Rachel Li
Employment or Leadership Position - Novartis
Carlos L. Arteaga
Consultant or Advisory Role - AstraZeneca; Genentech; Monogram Biosciences/LabCorp; Novartis; Roche/Genentech; Susan G. Komen for the Cure
Research Funding - AstraZeneca; OSI Pharmaceuticals; U3 Pharma-Daichi